clinical trial · NCT07783802
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Eli Lilly and Company·phase2·recruiting·n = 120
AtherosclerosisCardiovascular DiseaseObesityHypertensionDiabetes Mellitus, Type 2Renal Insufficiency, ChronicClazakizumabPlacebo
brief summary
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.
started
Aug 27, 2026
primary completion
May 1, 2027
completion
Oct 1, 2027
last updated
Sep 30, 2026
official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol